• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by BioSig Technologies Inc.

    5/15/25 4:43:12 PM ET
    $BSGM
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $BSGM alert in real time by email
    NT 10-Q 1 formnt10-q.htm NT 10-Q

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 12b-25

    NOTIFICATION OF LATE FILING

     

    (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D
      ☐ Form N-CEN ☐ Form N-CSR      

     

    For Period Ended: March 31, 2025

     

      ☐ Transition Report on Form 10-K
      ☐ Transition Report on Form 20-F
      ☐ Transition Report on Form 11-K
      ☐ Transition Report on Form 10-Q
      For the Transition Period Ended: ____________________

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.
    Nothing in this Form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

     

     

    PART I — REGISTRANT INFORMATION

     

    BioSig Technologies, Inc.
    Full Name of Registrant
     
     
    Former Name if Applicable
     
    12424 Wilshire Blvd, Ste 745
    Address of Principal Executive Office (Street and Number)
     
    Los Angeles, California 90025
    City, State and Zip Code

     

     

      

     

     

     

    PART II — RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

      (a) The reason described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense;
         
    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
         
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III — NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra Sheets if Needed)

     

    BioSig Technologies, Inc. (the “Company”) is unable to file its Quarterly Report on Form 10-Q (the “Form 10-Q”) for the period ended March 31, 2025, within the prescribed period. The compilation, dissemination and review of the financial information required to be presented in the Form 10-Q has imposed time constraints that have rendered timely filing of the Form 10-Q impractical without undue hardship and expense to the Company. At this time, the Company expects to file the Form 10-Q no later than the fifth calendar day following the prescribed due date.

     

    2

     

     

    PART IV — OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

    Anthony Amato   (203)   409-5444
    (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

     

    ☒ Yes ☐ No

     

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? 

     

    ☒ Yes ☐ No

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    For the three months ended March 31, 2025, compared to the three months ended March 31, 2024, the Company expects to report the following results of operations (dollars in thousands, other than per share numbers):

     

    Revenue for the three months ended March 31, 2025, was Nil as compared to $14 comprised of product sales of Nil and recognized service revenue of $14, for the three months ended March 31, 2024. Cost of sales for the three months ended March 31, 2025 and 2024, was Nil. Gross profit for the three months ended March 31, 2025, was Nil as compared to $14 for the three months ended March 31, 2024.

     

    Research and development expenses for the three months ended March 31, 2025, were approximately $6, a decrease of $232, or 97.48%, from $238 for the three months ended March 31, 2024.

     

    While the Company does not expect material changes to the aforementioned preliminary unaudited financial information, such preliminary financial information remains subject to change pending the completion of the Company’s financial statements as of and for the three months ended March 31, 2025.

     

    3

     

     

    BioSig Technologies, Inc.

     

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date May 15, 2025   By /s/ Ferdinand Groenewald
          Name: Ferdinand Groenewald
          Title: Interim Chief Financial Officer

     

    4

     

    Get the next $BSGM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BSGM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BSGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • The Benchmark Company initiated coverage on BioSig Technologies with a new price target

      The Benchmark Company initiated coverage of BioSig Technologies with a rating of Buy and set a new price target of $42.00

      2/8/21 7:32:50 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Williams Mitchell Young claimed ownership of 1,000,000 units of Restricted Common Stock (SEC Form 3)

      3 - BioSig Technologies, Inc. (0001530766) (Issuer)

      6/9/25 6:31:07 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 3 filed by new insider Mcphie Karl Henry Michael

      3 - BioSig Technologies, Inc. (0001530766) (Issuer)

      6/9/25 6:29:42 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 3 filed by new insider Lekstrom Morgan Lee

      3 - BioSig Technologies, Inc. (0001530766) (Issuer)

      6/9/25 6:27:01 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    SEC Filings

    See more
    • BioSig Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BioSig Technologies, Inc. (0001530766) (Filer)

      7/9/25 9:22:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - BioSig Technologies, Inc. (0001530766) (Filer)

      5/30/25 4:05:38 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - BioSig Technologies, Inc. (0001530766) (Filer)

      5/27/25 6:02:01 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioSig Technologies, Inc. and Streamex Exchange Corporation Announce Definitive Agreements for up to $1.1B USD in Growth Financing to Launch Gold Backed Treasury Management Strategy and to Rapidly Expand RWA Tokenization for the Commodities Markets

      BioSig Technologies, Inc. (NASDAQ:BSGM), which recently merged with Streamex Exchange Corporation ("Streamex") to become one of largest public holders of gold bullion. Streamex' proprietary real-world asset (the "RWA") platform will bring the approx. $142 trillion commodities market on the blockchain powered by Streamex & Solana. The transaction was led by: Cantor Fitzgerald & Co., Clear Street LLC and Needham & Company, LLC acting as placement agents; and CIBC World Markets acting as Strategic Advisor to the BSGM board of directors and management. BioSig Technologies, Inc. ("BioSig" or the "Company"), which recently merged with Streamex Exchange Corporation ("Streamex") (

      7/7/25 6:41:00 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig & Streamex Appoint Parcl Co-Founders Trevor Bacon and Kellan Grenier as Strategic Advisors

      Los Angeles, CA & Vancouver, BC, June 09, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig"), which acquired Streamex Exchange Corporation as its wholly owned subsidiary ("Streamex") in May 2025, is pleased to announce the appointment of Trevor Bacon and Kellan Grenier, co-founders of Parcl, as Strategic Advisors. Together, they bring deep expertise at the intersection of decentralized finance, synthetic asset creation, and real-world asset tokenization. Parcl is a leading blockchain-native platform that enables users to gain exposure to real estate markets through synthetic, perpetual trading. Built on Solana, the platform offers users the ability to speculate on

      6/9/25 10:30:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig & Streamex Appoint Co-Founder of the Osisko Group & Mining Visionary, Sean Roosen as Strategic Advisor

      Los Angeles, CA and Vancouver, BC, June 04, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig"), which acquired Streamex Exchange Corporation as its wholly owned subsidiary ("Streamex") in May 2025, is pleased to announce the appointment of Sean Roosen as Strategic Advisor to Streamex. Mr. Roosen, a globally recognized mining entrepreneur and financier, brings over three decades of experience in building and scaling multibillion-dollar resource ventures. Mr. Roosen is the Founder, Executive Chairman, and Chief Executive Officer of Osisko Development Corp., a premier North American gold development company. He is also the founder and former Executive Chairman and CE

      6/4/25 8:25:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BioSig Technologies Inc.

      SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

      11/14/24 3:58:00 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by BioSig Technologies Inc.

      SC 13G - BioSig Technologies, Inc. (0001530766) (Subject)

      2/14/24 3:31:45 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by BioSig Technologies, Inc. (Amendment)

      SC 13G/A - BioSig Technologies, Inc. (0001530766) (Subject)

      7/12/21 8:29:21 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    Leadership Updates

    Live Leadership Updates

    See more
    • BioSig & Streamex Appoint Parcl Co-Founders Trevor Bacon and Kellan Grenier as Strategic Advisors

      Los Angeles, CA & Vancouver, BC, June 09, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig"), which acquired Streamex Exchange Corporation as its wholly owned subsidiary ("Streamex") in May 2025, is pleased to announce the appointment of Trevor Bacon and Kellan Grenier, co-founders of Parcl, as Strategic Advisors. Together, they bring deep expertise at the intersection of decentralized finance, synthetic asset creation, and real-world asset tokenization. Parcl is a leading blockchain-native platform that enables users to gain exposure to real estate markets through synthetic, perpetual trading. Built on Solana, the platform offers users the ability to speculate on

      6/9/25 10:30:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig & Streamex Appoint Co-Founder of the Osisko Group & Mining Visionary, Sean Roosen as Strategic Advisor

      Los Angeles, CA and Vancouver, BC, June 04, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig"), which acquired Streamex Exchange Corporation as its wholly owned subsidiary ("Streamex") in May 2025, is pleased to announce the appointment of Sean Roosen as Strategic Advisor to Streamex. Mr. Roosen, a globally recognized mining entrepreneur and financier, brings over three decades of experience in building and scaling multibillion-dollar resource ventures. Mr. Roosen is the Founder, Executive Chairman, and Chief Executive Officer of Osisko Development Corp., a premier North American gold development company. He is also the founder and former Executive Chairman and CE

      6/4/25 8:25:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CORRECTION: Streamex and BioSig Appoint Former OppenheimerFunds and Wafra Inc Executive, Mitch Williams, CFA, as Chief Investment Officer (CIO)

      Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig") and Streamex Exchange Corporation ("Streamex"), collectively referred to as the combined company, today announced the appointment of Mitch Williams, CFA, as Chief Investment Officer significantly bolstering the companies' leadership team and advancing the mission to tokenize real world assets and bring commodity markets on-chain. Key Highlights of the Appointment: Mr. Mitch Williams, former OppenheimerFunds and Wafra Inc. executive and Strategic Advisor to Streamex will be appointed Chief Investment Officer of the combined company. Mr, Williams, brings over 20 years of

      5/28/25 6:45:00 PM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BSGM
    Financials

    Live finance-specific insights

    See more
    • BioSig Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module

      Westport, CT, Sept. 22, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today announced the release of PURE EP™ Software Version 6 with ACCUVIZ™ Module. Built around three highly differentiating features, PURE EP™ Software Version 6 with ACCUVIZ™ Module introduces the proprietary High Frequency Algorithm (HFA), a novel feature that identifies the key frequency components of cardiac data that can be difficult to identify within the traditional waveform presentation. O

      9/22/22 9:00:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BioSig to Host Conference Call on December 21, 2021

      Westport, CT, Dec. 13, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a conference call on Tuesday, December 21, 2021, at 2 PM ET. Conference Call DetailsDate: Tuesday, December 21, 2021Time: 2:00 PM Eastern Time (ET)Dial-in number for US callers (toll-free): 877-407-8293Dial-in number for U.S. and international callers (toll): +1 201-689-8349 To join the conference call online, please click here: BioSig Webcast A

      12/13/21 8:30:00 AM ET
      $BSGM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care